# OnCo record gepardouze (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/gepardouze/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "gepardouze", "NCT03281954" ;
  schema:name "GeparDouze / NSABP B-59"@en ;
  schema:alternateName "NSABP B-59"@en, "GBG 96"@en, "GeparDouze"@en ;
  schema:description "GeparDouze, the largest neoadjuvant immunotherapy trial in triple-negative breast cancer, found that adding atezolizumab to chemotherapy before and after surgery did not significantly reduce relapses (a 3.3-point gain at four years that missed statistical significance), unlike pembrolizumab in KEYNOTE-522."@en ;
  schema:url <https://onco.cc/trials/gepardouze/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03281954>, <https://doi.org/10.1038/s41591-026-04565-6> ;
  onco:status "negative" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/epirubicin/>, <https://onco.cc/drugs/cyclophosphamide/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/gbg/> ;
  onco:terms <https://onco.cc/terms/efs/>, <https://onco.cc/terms/irae/>, <https://onco.cc/terms/tils/> ;
  onco:trials <https://onco.cc/trials/keynote-522/>, <https://onco.cc/trials/neotrip/>, <https://onco.cc/trials/impassion030/>, <https://onco.cc/trials/impassion031/> .